Angioimmunoblastic T cell lymphoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. AITL patients were confirmed by pathology. 2. First-line treatment with Anthracycline does not result in complete remission or disease progression during any course of treatment or relapse at any time. 3. At least one measurable lesion was required for any lymph node lesion larger than 1.5 cm in length or extranodal lesion larger than 1 cm in length and PET lesion uptake (SUV greater than hepatic blood pool). 4. Age 18-70, male or female. 5. ECOG score is 0-2. 6. Obtain informed consent signed by the patient or family member.
Exclusion criteria
Exclusion criteria: 1. Received systemic or local treatment including chemotherapy in the first three weeks. 2. Liver and kidney function: blood bilirubin > 2 mg/dl (35 umol/L), AST/ALT was more than 2 times of the upper limit of normal, serum creatinine was more than 177 umol/L, the creatinine clearance rate was less than 60 ml/min. 3. Normal heart function: EF <= 50%. 4. The expected survival time was less than 3 months. 5. Chronic or current active infectious diseases requiring systemic antibiotics, antifungal agents or antiviral therapy. 6. Other concurrent and uncontrollable factors are considered by the researchers to affect the medical status of patients participating in the study. Psychiatric patients or other patients who are known or suspected to be unable to fully comply with the study protocol. 7. People living with HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Safety;Safety; | — |
Countries
China
Contacts
The First Affiliated Hospital, College of Medicine, Zhejiang University